NCT06626516 2025-11-28
Tebentafusp-tebn With LDT in Metastatic UM
Thomas Jefferson University
Phase 1/2 Recruiting
Clinical Trials
6 trialsNCT02275416 2024-12-16
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
Ultimovacs ASA
Phase 1/2 Completed
NCT02009397 2021-11-22
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
University of Louisville
Phase 1/2 Completed
NCT03282188 2018-05-04
REO13 Melanoma With of Without GM-CSF
University of Leeds
Phase 1/2 Withdrawn
NCT00089219 2014-11-20
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
University of Virginia
Phase 1/2 Completed
NCT00204516 2013-01-16
Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens
University Hospital Tuebingen
Phase 1/2 Completed